Why a universal antiretroviral regimen?

Citation: Flexner CW, Clayden P, Venter WDF. Why a universal antiretroviral regimen? Curr Opin HIV AIDS. 2017 Jul;12(4):315-317. doi: 10.1097/COH.0000000000000390. PMID: 28486340. PMCID: PMC5722220.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/28486340

In 2015, with its "Treat all" recommendation, World Health Organization (WHO) removed all restrictions on eligibility for antiretroviral treatment (ART) among HIV positive people. WHO estimates that by the end of 2018, 20 million people worldwide will be receiving combination ART. An additional 15–17 million will be in need of ART but unable to access or afford it [1]. Most of the existing supply of antiretrovirals (ARVs) is provided through international agencies, such as PEPFAR and the Global Fund, or governments of low- and middle-income countries (LMICs), all of which face stable or shrinking health care budgets.

The economic challenges facing global provision of ARVs alone represent an overwhelming barrier to full treatment access. When combined with the logistical and implementation barriers, civil unrest, increasing ARV drug resistance worldwide, and continued issues with stigma in many parts of the world, it is hard to imagine how the treatment needs of all people with HIV can be met with existing programs and resources.

Categories

CRS
Topics

Clinical Trials

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More